[{"orgOrder":0,"company":"Libytec Pharmaceutical","sponsor":"Cosmos Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Agreement","leadProduct":"Thiocolchicoside","moa":"GABAA receptor alpha-1","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Libytec Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Libytec Pharmaceutical \/ Libytec Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Libytec Pharmaceutical \/ Libytec Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Libytec Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The agreement will support the clinical development of Thiocolchicoside for painful muscle spasms by targeting the GABAA receptor alpha-1.

                          Product Name : PathMuscle

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 05, 2026

                          Lead Product(s) : Thiocolchicoside,Paracetamol

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Recipient : Cosmos Health

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank